London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This one sorry.
“The positive results from the trial now enable the Company to:
· Confirm NXP001's potential for development as a treatment for CINV, enabling current and future licensees to launch new products into the £16bn oncology supportive care market
· Trigger a final milestone payment of £2m from its Chinese licensing partner, Newsummit Biopharma, who have commenced product registration in China (Nuformix retains 10% royalty, with remaining milestone payments expected during June 2019)
· Progress on-going discussions for licensing rest of world rights to NXP001 for CINV
· Finalise further product development opportunities for the NXP001 programme to generate additional future value
· Progress its wider portfolio using the Company's proven approach in identifying high-value applications for cocrystal technology
You have been posting on this bulletin board for the last few weeks like a person possessed yet you sold out etc etc.
I find it strange that you don’t even understand that NXP001 has passed all trials and is technically passed stage three drug ready to be packaged up by the companies who take it on and sold as a drug used all around the world to prevent CINV. What bit of derisked in that fact do you not understand.
“Nuformix' first clinical study for NXP001 completed on 22 April 2019 in a cross-over study that aimed to measure the relative bioavailability of NXP001 compared to Merck's EMEND® in healthy subjects. All enrolled subjects completed the study and were discharged without adverse effects, with results expected by end H1 2019.
Prior to entry to the clinic, Nuformix carried out an additional studies to further validate it's prototype NXP001 cocrystal formulations. NSB's acceptance of success in this work announced today brings the total milestone payments from NSB to £1 million, with a further £2 million payment due dependant on relative human bioavailability results, as per the agreement for NXP001 marketing and distribution in China.
Commenting on the news, Dr Dan Gooding, CEO of Nuformix, said: "We're delighted to have reached this second pre-clinical milestone. The data generated was not only sufficient to trigger a second payment of £500k with NewsummitBio, but also gave us tremendous confidence to make the next step into human studies. We look forward to sharing human data very soon and continue to work closely with NSB, such is their commitment to the commercialisation of NXP001 and its understanding of the commercial opportunity in China. Milestone revenues continue to validate Nuformix's business model and its commitment to reinvest early revenues back into R&D, avoiding further fund-raising at this stage whilst maximising the potential value of its cocrystal platform."
Multi billion pound market
Alibi , its 30mill mcap and weve already got 1 drug passed through trials that we can market all over the world. Its easy to fall for a story but also all to easy to forget the huge success so far this year. I would argue this is not far derisked at current mcap.
As soon as / if we receive chinese cash this will fly back towards 10p. Listen to dans recent podcast again on vx, he always chooses his words carefully but it was full of intent about payment and i think we ll get an update on this next week.
Lot of potential here, also definitely not derisked yet. I'm already in a nailbiting stock and don't need another one at the moment but will get back in when I rebalance and things look clearer and I imagine they should in a few months time.
Not saying you may be biased particularly more an observation on my part on how easy it is to fall in love with a good story and filter out negative news.
Not biased alibi just still very confident with the long term prospects here. I have plenty of reservations im not blind to them, short term this could go either way....big sell from cpl, no cash from chinese could send this lower still but neither of those change the fact were on the brink of nxp002 trials. Wether we are 6p or 12p right now doesnt hugely matter to me as im here long term and wont be selling until we get through trials. I personally think dan and joanne deserve their salaries for many of the reasons jay gave
Appreciate your response, and fair points but wouldn't agree they get paid very little at this point of the company's growth.
Interesting article(s) on seeking alpha.com regarding cannabis/cannabinoids etc(American website so heavily biased).Search seeking alpha....once on website search cannabis investing podcast.
They could of gone private Albi as a company.
What did they pay?
Well 20 plus years of their lives, the PHD and knowledge. Co Crystal is cutting edge. They have a lot of skin in the game (joanne/Dan also have 50 mill in performance warrants)
So No taker/sell out without them.
They are an amazing team.. We are lucky to be invested. As for any wage cuts? They get paid very little.. They are building the company. Low cost.
CDub Apparently the resigned Director was not that hot at his job simples. !!!!!
On balance your post I agree with and have done the same myself. I would, however, if you permit, ask whether you think perhaps the BoD's salary at this point is really reasonable? Could they perhaps knock a bit off while so much is in the balance?
Everything you say is perfectly reasonable and relatable - however, beware of investor bias. Once we have committed our £ or $ to something it's rather hard to stay objective.
That's said with all empathy, we're all investors here or elsewhere and it can be a hard ride at times.
I'm so sorry, what did the current BoD pay for their shares?
Gp, just 1 reason to stay confident. They own a large % which was a big reason why i got involved to start with.
The big thing the bod have shares deep and are aiming for a sell out .you don't mug yourself,
The story so far is good , nfx derisked ,
Just get rid of the seller and most of the problems gone ,
I didn't see the seller today ?
You just need patience here
Cdub its a been a rough 3 months, i have not sold a bean and of course i wish i had sold in the teens but i have decided to stick with my holding. Its quite stressful at times, my holding is now down well over 120k from the highs but the story is still the same here if you have a positive frame of mind.
read up on everything possible and that settles my nerves. Im lucky to have got in here at 3p all the way up to 11p ish. Just go with your gut feeling, if its too risky sell up but i still believe in dan and the board. This is a long term play dont let the chancers on here (inc me) swerve you either way .
also this is a startup pharma, i doubt not one in history has been plain sailing. Im always wary of pharmas as the chances of success long term are low but nfx are playing a different game.
Nxp001 is proven (remember ROW licensing may take up to a year to sort) nxp002 is the golden ticket, research research research. I havent lost a wink of sleep so far with nfx myself.
No word of a lie it’s been a tough week, I have been questioning my holdings here several times. I have spent Friday evening reading the most recent financial report, reading every last detail. I have examined my investment decision as much as I possibly can. I can safely say what I have seen has made me certain I will hold and buy more on any good news. When you look through the accounts you can see this is a shrewd operation. There aren’t the normal red flags here; no bloated salaries, dodgy expenses, spike sell-offs etc. The resignation is a bit of a blow but there is a multitude of possible innocuous reasons which we need to factor into the equation. People come and go from jobs in growing businesses all the time. Sometimes you can suddenly start questioning everything and the scam siren goes off in your head but when you evaluate all the effort put in, with all the expertise of the staff, the trial passes and the fact New Summit’s paid a £mill and Ebers half, and the shrewdness of the operation, you think there must be something there and that thing should be damn good. Time will tell :)
Dajjas, i spoke to spreadex 3 times this year about sell orders on their nuformix stock. The first 2 times back in june / july ish i was told they have no sell orders in at this present time indicating to me they held stock but werent actively selling on that day. Overall the guy was quite helpful. I called for the last time yesterday and the same guy wouldnt give any info at all. He just kept saying i cant disclose what we hold, its below 3% as per rns. Glass half full Maybe they have finally sold out completely and they now just shut up and give no info out at all. Or hes brassed off witb people calling him up about nfx !! If cpl have indeed stopped and taken advice from dan gooding regards any more sales next week might be a bit rosier for us all. Any 100k sales today?
when will the selling stop.
I am assuming once we hear good news re: the Chinese money.
Not mentioned on this, but came across this earlier.
https://www.hempandcbdexpo.co.uk/september-exhibitors-list/. Thought it might be of interest as Nfx is into hemp/cannabis extract.
Apologies if already known.
Haha, I was just about to say the two 20k trades look like an ISA...lucky lady.
well I can not believe my luck. bed and isa at 6.6 to the wife.. happy days..
Two very different conditions ,not cystic fibrosis
Guys please do your research. CF is not the same as IPF!!
biboergosum, A friend also asked and got the same reply. As best as I understand it, Cystic Fibrosis is an overproduction of mucus(?) that sits on the lungs and has to be continually massaged away.
Considering on tests so far this beats anything current on the market by miles. In fact nothing currently is of much good then the value on this is huge.
Effectively this will be the only real treatment available on a multi billion dollar market. That’s just one spinoff from NXP002. There will be multiple spinoffs. This will succeed just like NXP001 has.
This is the size of the current potential market to which this minor is taking hold of. ;)